These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32206236)

  • 1. Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM; David T; Pagare PP; Ghatge MS; Chen Q; Mehta A; Zhang Y; Abdulmalik O; Naghi AH; El-Araby ME; Safo MK
    Medchemcomm; 2019 Nov; 10(11):1900-1906. PubMed ID: 32206236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
    Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
    Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
    J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
    Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
    Abdulmalik O; Ghatge MS; Musayev FN; Parikh A; Chen Q; Yang J; Nnamani I; Danso-Danquah R; Eseonu DN; Asakura T; Abraham DJ; Venitz J; Safo MK
    Acta Crystallogr D Biol Crystallogr; 2011 Nov; 67(Pt 11):920-8. PubMed ID: 22101818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
    Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
    Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
    Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisickling Drugs Targeting βCys93 Reduce Iron Oxidation and Oxidative Changes in Sickle Cell Hemoglobin.
    Kassa T; Wood F; Strader MB; Alayash AI
    Front Physiol; 2019; 10():931. PubMed ID: 31396101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
    Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
    Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of red cell sickling. Effects of varying pH and of increasing intracellular hemoglobin concentration by osmotic shrinkage.
    Bookchin RM; Balazs T; Landau LC
    J Lab Clin Med; 1976 Apr; 87(4):597-616. PubMed ID: 5563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
    Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rates and properties of sickle cell anemia red cells treated with nitrogen mustard.
    Roth EF; Wenz B; Lee HB; Fabry M; Chang H; Kaul DK; Baez S; Nagel RL
    Prog Clin Biol Res; 1987; 240():245-61. PubMed ID: 3615491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease.
    Alhashimi RT; Ghatge MS; Donkor AK; Deshpande TM; Anabaraonye N; Alramadhani D; Danso-Danquah R; Huang B; Zhang Y; Musayev FN; Abdulmalik O; Safo MK
    Biomolecules; 2022 May; 12(5):. PubMed ID: 35625623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E; Safo MK; Abdulmalik O; Kato GJ
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.